{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:26:57Z","timestamp":1784647617721,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T00:00:00Z","timestamp":1624492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00262-021-02989-2","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T12:02:40Z","timestamp":1624536160000},"page":"353-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody"],"prefix":"10.1007","volume":"71","author":[{"given":"Haiqing","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianka","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanta","family":"Baruah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5605-6837","authenticated-orcid":false,"given":"Weiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"2989_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/annonc\/mdy041","volume":"29","author":"EE Vokes","year":"2018","unstructured":"Vokes EE, Ready N, Felip E et al (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29:959\u2013965. https:\/\/doi.org\/10.1093\/annonc\/mdy041","journal-title":"Ann Oncol"},{"key":"2989_CR2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389:2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"key":"2989_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271\u2013285. https:\/\/doi.org\/10.1016\/j.cell.2009.05.046","journal-title":"Cell"},{"key":"2989_CR4","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044","journal-title":"Cell"},{"key":"2989_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","volume":"138","author":"R Majeti","year":"2009","unstructured":"Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286\u2013299. https:\/\/doi.org\/10.1016\/j.cell.2009.05.045","journal-title":"Cell"},{"key":"2989_CR6","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1073\/pnas.1121623109","volume":"109","author":"SB Willingham","year":"2012","unstructured":"Willingham SB, Volkmer J-P, Gentles AJ et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci 109:6662\u20136667. https:\/\/doi.org\/10.1073\/pnas.1121623109","journal-title":"Proc Natl Acad Sci"},{"key":"2989_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/0008-5472.CAN-10-2238","volume":"71","author":"MP Chao","year":"2011","unstructured":"Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71:1374\u20131384. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2238","journal-title":"Cancer Res"},{"key":"2989_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14102-4","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang M, Wang X, Liu W, Wang H, Yang Y-G (2020) Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-019-14102-4","journal-title":"Nat Commun"},{"key":"2989_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nm.3965","volume":"21","author":"RH Vonderheide","year":"2015","unstructured":"Vonderheide RH (2015) CD47 blockade as another immune checkpoint therapy for cancer. Nat Med 21:1122\u20131123. https:\/\/doi.org\/10.1038\/nm.3965","journal-title":"Nat Med"},{"key":"2989_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1091\/mbc.E09-07-0590","volume":"21","author":"N Ferrara","year":"2010","unstructured":"Ferrara N (2010) Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell 21:687\u2013690. https:\/\/doi.org\/10.1091\/mbc.E09-07-0590","journal-title":"Mol Biol Cell"},{"key":"2989_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/nm1010-1107","volume":"16","author":"N Ferrara","year":"2010","unstructured":"Ferrara N (2010) Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nat Med 16:1107\u20131111. https:\/\/doi.org\/10.1038\/nm1010-1107","journal-title":"Nat Med"},{"key":"2989_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nm0603-685","volume":"9","author":"RK Jain","year":"2003","unstructured":"Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685\u2013693. https:\/\/doi.org\/10.1038\/nm0603-685","journal-title":"Nat Med"},{"key":"2989_CR13","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4049\/jimmunol.0900397","volume":"184","author":"A Basu","year":"2010","unstructured":"Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, Calzadilla K, Pal S, Briscoe DM (2010) Cutting edge: Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-gamma production. J Immunol 184:545\u2013549. https:\/\/doi.org\/10.4049\/jimmunol.0900397","journal-title":"J Immunol"},{"key":"2989_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1096-1096","volume":"2","author":"DI Gabrilovich","year":"1996","unstructured":"Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096\u20131103. https:\/\/doi.org\/10.1038\/nm1096-1096","journal-title":"Nat Med"},{"key":"2989_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M et al (2012) VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. Int J Cancer 130:857\u2013864. https:\/\/doi.org\/10.1002\/ijc.26094","journal-title":"Int J Cancer"},{"key":"2989_CR16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","volume":"30","author":"AM Bolger","year":"2014","unstructured":"Bolger AM, Lohse M, Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114\u20132120. https:\/\/doi.org\/10.1093\/bioinformatics\/btu170","journal-title":"Bioinformatics"},{"key":"2989_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR (2013) STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29:15\u201321. https:\/\/doi.org\/10.1093\/bioinformatics\/bts635","journal-title":"Bioinformatics"},{"key":"2989_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W (2015) HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166\u2013169. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638","journal-title":"Bioinformatics"},{"key":"2989_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"2989_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W da Huang","year":"2009","unstructured":"da Huang W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37:1\u201313. https:\/\/doi.org\/10.1093\/nar\/gkn923","journal-title":"Nucleic Acids Res"},{"key":"2989_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W da Huang","year":"2009","unstructured":"da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44\u201357. https:\/\/doi.org\/10.1038\/nprot.2008.211","journal-title":"Nat Protoc"},{"key":"2989_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette A, Chen J (2018) SIRP\u03b1-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol 39:173\u2013184. https:\/\/doi.org\/10.1016\/j.it.2017.12.005","journal-title":"Trends Immunol"},{"key":"2989_CR23","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.4049\/jimmunol.159.11.5661","volume":"159","author":"WL Trepicchio","year":"1997","unstructured":"Trepicchio WL, Wang L, Bozza M, Dorner AJ (1997) IL-11 regulates macrophage effector function through the inhibition of nuclear factor-kappaB. J Immunol 159:5661\u20135670","journal-title":"J Immunol"},{"key":"2989_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.bbrep.2016.01.009","volume":"5","author":"A Shiraki","year":"2016","unstructured":"Shiraki A, Kotooka N, Komoda H, Hirase T, Oyama JI, Node K (2016) Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep 5:290\u2013295. https:\/\/doi.org\/10.1016\/j.bbrep.2016.01.009","journal-title":"Biochem Biophys Rep"},{"key":"2989_CR25","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.4049\/jimmunol.1403196","volume":"194","author":"J Bai","year":"2015","unstructured":"Bai J, Liu Z, Xu Z et al (2015) Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis. J Immunol 194:4185\u20134198. https:\/\/doi.org\/10.4049\/jimmunol.1403196","journal-title":"J Immunol"},{"key":"2989_CR26","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1242\/jcs.114.6.1061","volume":"114","author":"RC May","year":"2001","unstructured":"May RC, Machesky LM (2001) Phagocytosis and the actin cytoskeleton. J Cell Sci 114:1061\u20131077","journal-title":"J Cell Sci"},{"key":"2989_CR27","doi-asserted-by":"publisher","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","volume":"113","author":"JT Sockolosky","year":"2016","unstructured":"Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, Garcia KC (2016) Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci USA 113:E2646\u2013E2654. https:\/\/doi.org\/10.1073\/pnas.1604268113","journal-title":"Proc Natl Acad Sci USA"},{"key":"2989_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf K, Ring AM, Ho CCM et al (2013) Engineered SIRP\u03b1 variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341:88\u201391. https:\/\/doi.org\/10.1126\/science.1238856","journal-title":"Science"},{"key":"2989_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imm.12290","volume":"143","author":"LS Kwong","year":"2014","unstructured":"Kwong LS, Brown MH, Barclay AN, Hatherley D (2014) Signal-regulatory protein \u03b1 from the NOD mouse binds human CD47 with an exceptionally high affinity\u2013 implications for engraftment of human cells. Immunology 143:61\u201367. https:\/\/doi.org\/10.1111\/imm.12290","journal-title":"Immunology"},{"key":"2989_CR30","doi-asserted-by":"publisher","first-page":"12650","DOI":"10.1074\/jbc.M115.648220","volume":"290","author":"CCM Ho","year":"2015","unstructured":"Ho CCM, Guo N, Sockolosky JT, Ring AM, Weiskopf K, \u00d6zkan E, Mori Y, Weissman IL, Garcia KC (2015) \u201cVelcro\u201d engineering of high affinity CD47 ectodomain as signal regulatory protein \u03b1 (SIRP\u03b1) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem 290:12650\u201312663. https:\/\/doi.org\/10.1074\/jbc.M115.648220","journal-title":"J Biol Chem"},{"key":"2989_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.7","author":"EC Pietsch","year":"2017","unstructured":"Pietsch EC, Dong J, Cardoso R et al (2017) Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. https:\/\/doi.org\/10.1038\/bcj.2017.7","journal-title":"Blood Cancer J"},{"key":"2989_CR32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-120170","author":"D Feng","year":"2018","unstructured":"Feng D, Gip P, McKenna KM et al (2018) Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia. Blood. https:\/\/doi.org\/10.1182\/blood-2018-99-120170","journal-title":"Blood"},{"key":"2989_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02989-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02989-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02989-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T11:11:17Z","timestamp":1672571477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02989-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2989"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02989-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"15 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bianka Prinz, Hemanta Baruah and James Geoghegan have no potential conflicts of interest to disclose. All other authors are employees of Innovent Biologics (Suzhou).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All mice were maintained under pathogen-free conditions in the Experimental Animal Center of Innovent Biologics Co., Ltd. (Suzhou, China). All mice-related experiments were approved by the Animal Use and Care Committee of Innovent Biologics.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}